^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Allo WT1-TCR

    i
    Other names: Allo WT1-TCR, NTLA-5001
    Associations

    News

    Trials
    Company:
    Intellia Therap
    Drug class:
    Wilms tumor 1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    over1year
    Study Investigating NTLA-5001 in Subjects With Acute Myeloid Leukemia (clinicaltrials.gov)
    P1/2, N=6, Terminated, Intellia Therapeutics | N=54 --> 6 | Trial completion date: Sep 2025 --> Aug 2022 | Active, not recruiting --> Terminated | Trial primary completion date: Nov 2023 --> Jul 2022; Pivoting to an allogeneic version of this program currently in preclinical development.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    HLA-A (Major Histocompatibility Complex, Class I, A)
    |
    HLA-A*02
    |
    cyclophosphamide • Allo WT1-TCR
    almost2years
    Study Investigating NTLA-5001 in Subjects With Acute Myeloid Leukemia (clinicaltrials.gov)
    P1/2, N=54, Active, not recruiting, Intellia Therapeutics | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HLA-A (Major Histocompatibility Complex, Class I, A)
    |
    HLA-A*02
    |
    cyclophosphamide • Allo WT1-TCR
    over2years
    Study Investigating NTLA-5001 in Subjects With Acute Myeloid Leukemia (clinicaltrials.gov)
    P1/2, N=54, Recruiting, Intellia Therapeutics | Not yet recruiting --> Recruiting
    Clinical • Enrollment open
    |
    HLA-A (Major Histocompatibility Complex, Class I, A)
    |
    HLA-A*02
    |
    Allo WT1-TCR
    over2years
    Clinical-Scale Production and Characterization of Ntla-5001 - a Novel Approach to Manufacturing CRISPR/Cas9 Engineered T Cell Therapies (ASH 2021)
    In addition, NTLA-5001 drug product displayed cytotoxic functionality when exposed to cell lines presenting the target WT1 peptide. The NTLA-5001 clinical-scale manufacturing process is a controlled and robust platform for the generation of minimally differentiated T cells with high rates of editing and transgene expression.
    Clinical • IO biomarker
    |
    CD8 (cluster of differentiation 8) • HLA-A (Major Histocompatibility Complex, Class I, A) • WT1 (WT1 Transcription Factor) • CD4 (CD4 Molecule) • TRB (T Cell Receptor Beta Locus) • SELL (Selectin L)
    |
    Allo WT1-TCR
    over2years
    Study Investigating NTLA-5001 in Subjects With Acute Myeloid Leukemia (clinicaltrials.gov)
    P1/2, N=54, Not yet recruiting, Intellia Therapeutics
    Clinical • New P1/2 trial
    |
    HLA-A (Major Histocompatibility Complex, Class I, A)
    |
    Allo WT1-TCR
    over3years
    [VIRTUAL] NTLA5001, a T Cell Product Candidate with CRISPR-Based Targeted Insertion of a High-Avidity, Natural, WT1-Specific TCR, Shows Efficacy in In Vivo Models of AML and ALL (ASH 2020)
    This can be achieved with CRISPR/Cas9-mediated replacement of the endogenous TCR α and β chains, by knocking out the TRAC and TRBC genes and inserting the tgTCR into the TRAC locus. NTLA-5001 is being advanced into clinical development for AML immunotherapy. Given the expression of WT1 in many solid tumors, engineered WT1 TCR-T cells are being further explored in those indications.
    Preclinical • IO biomarker
    |
    CD8 (cluster of differentiation 8) • WT1 (WT1 Transcription Factor)
    |
    Allo WT1-TCR